XPRIZE Healthspan Results, Audited Against the Rules

The AgelessRx XPRIZE Healthspan results landed with the familiar shape of longevity news: an encouraging interim readout, a milestone award, headlines that treat both as progress toward defeated aging. Strip the celebration and one fact organizes everything else. XPRIZE's published design calls for roughly a 12-month intervention in adults aged 65 to 80, scored on tested restoration of muscle, cognitive, and immune function. A 90-day readout, issued by the team's own sponsor, covers about a quarter of that window and answers a different question than the contest asks. It functions as a feasibility signal, and at 90 days it was never going to be more.

That verdict requires arithmetic, not cynicism. And the same four questions that produce it (duration versus endpoint, surrogate versus tested function, self-report versus performance, funding and publication status) will audit any longevity press release you read this year. This piece runs the AgelessRx announcement through those questions, then stress-tests the method on four claims you have already met elsewhere: consumer epigenetic clocks, NAD+ precursors, young-donor plasma, and the PEARL rapamycin trial.

What AgelessRx Actually Announced

Start with what the announcement verifiably says. Per the AgelessRx Milestone 2 announcement, AgelessRx was named an XPRIZE Healthspan Milestone 2 awardee and awarded $1 million to advance its healthy-aging clinical trial, with an interim readout from the first 90 days attached. Three facts in that sentence do most of the work.

• The award advances a trial. Milestone money at this stage is designed to fund execution and readiness: enrollment, baseline completion, protocol discipline. That is a real achievement and a different thing from a result.
• The 90-day data is sponsor-issued. AgelessRx ran the intervention, collected the observations, chose what to highlight, and distributed the release. Every number may be honestly measured; every framing choice was still made by the party with the most to gain from a favorable read.
• The issuer sells the category. AgelessRx is a commercial telehealth company that markets longevity prescriptions and at-home testing. It fields a competing team and monetizes the market that team competes in. That does not make its data wrong; it tells you which incentives selected the words around the data.

Note which parts of a typical release are adjectives and which are measurements. "Promising," "encouraging," and "on track" describe a sponsor's mood. Duration, sample size, blinding, endpoints, and publication status describe evidence. The rest of this article uses only the second kind.

What XPRIZE Healthspan Results Are Actually Scored On

To judge these XPRIZE Healthspan results you need the measuring stick, and XPRIZE published theirs. The XPRIZE Healthspan competition overview specifies a roughly 12-month therapeutic intervention in adults aged 65 to 80, with teams scored on restoring muscle, cognitive, and immune function toward a more youthful profile, and on tests of that function rather than biomarker shifts alone.

The purse explains why the design is strict: $101 million, billed as the largest health prize in XPRIZE's history, announced with major support from the Hevolution Foundation. If you have wondered who funds XPRIZE Healthspan, the answer is foundation capital at a scale that tells you exactly how much money rides on healthspan intervention evidence.

Give the contest its due. Tested function over 12 months in older adults is a stricter bar than most published industry trials clear, and stricter than nearly every consumer longevity claim on the market. That strictness is the point. The same yardstick that makes XPRIZE Healthspan credible makes a 90-day sponsor readout small. The prestige and the scoring rules are a package deal.

Why 90 Days Cannot Show What 12 Months Tests

The arithmetic first. Ninety days is roughly 25 percent of a 365-day intervention window, and it is the least informative 25 percent: the opening quarter, before plateaus, attrition, adaptation, or washout have said anything. So, are 90-day longevity trial results meaningful? Yes, for a narrow set of questions, and no for the ones the prize money actually bets on.

The XPRIZE Healthspan 90-day trial readout therefore lands in the feasibility column. It can tell you the intervention was taken, generally tolerated, and visible in short-window markers. It cannot tell you whether tested function in a 65-to-80-year-old moved and stayed moved. Any headline crossing that line is borrowing 12 months of credibility that does not exist yet.

Surrogate Biomarkers vs Tested Function

A surrogate endpoint is a stand-in you measure instead of the thing you care about, and the surrogate endpoints aging research leans on most, epigenetic clocks, blood NAD, inflammatory panels, are stand-ins precisely because real outcomes take years. The FDA-NIH endpoint taxonomy is blunt on this point: a biomarker earns surrogate status only after evidence shows that moving it reliably moves the clinical outcome. For aging, that validation has not happened. No regulator has accepted any biological-age clock as a validated substitute for tested function, which is a working explanation for why XPRIZE built its scoring around function in the first place.

Biological age clocks versus functional outcomes is the sharpest version of the gap. A clock can report that a methylation pattern shifted by a few "years"; it cannot report that a person regained grip strength, processing speed, or immune competence, and the mapping between clock deltas and functional change remains loose and method-dependent. Two clocks can disagree about the same person, which is disqualifying for anything asked to carry a proof of concept alone.

NAD+ precursors show the pattern in its purest form. A review of NAD+ precursor trials finds that nicotinamide riboside and NMN reliably raise blood NAD, and largely stop there; evidence for gains in tested function remains limited and mixed. When a 90-day readout leads with biomarker movement, translate it as "the intervention is bioavailable," which is worth knowing and nowhere near the prize question.

Self-Reports vs Tested Capacity

The second downgrade is subtler. Energy, mood, sleep quality, and wellness scores are patient-reported outcomes, a legitimate tier of evidence and the easiest one to inflate without anyone lying. Expectancy effects are measurable: when people know they received an active intervention, their self-ratings improve more than their performance does, a gap documented in comparisons of expectancy effects on patient-reported outcomes.

In an unblinded, sponsor-run pilot, the inflation compounds. Participants know what they took. The sponsor chose the instrument, the timing, and which ratings to highlight. Nobody has to fake anything for "participants reported improved energy" to emerge from a cohort whose grip strength and cognitive batteries moved not at all. The contest's answer is to test capacity, grip, gait speed, timed cognitive batteries, quantified immune response, because performance under measurement resists wishful thinking. When you read a release, sort every claimed outcome into those two piles before deciding what happened.

Funding and Publication Status, Checked in Minutes

None of the above requires trusting anyone. Two checks take about five minutes each, and between them they capture most of how to read clinical trial results at the consumer level.

Check one, registration

ClinicalTrials.gov publishes registered interventional trials with their design, enrollment, endpoints, and status, and its guide to reading study records explains every field. A registered trial with prespecified endpoints is a commitment made in advance. Without registration, a sponsor can measure twelve endpoints and headline the two that moved, which is the industry's signature move and the main thing registration defends against.

Check two, publication

If you want to know how to check if a study is peer reviewed, the method is one search: PubMed for the reviewed paper, preprint servers for drafts. A preprint means the authors shared a draft, and preprints are not peer reviewed, whatever their quality. A longevity trial press release with neither registration nor publication is marketing wearing the texture of data. Absence does not prove a claim false. It reliably lowers how much you should update on it, and how much you should spend because of it.

Then look at who is talking. When one company funds the team, issues the release, and sells products in the category the release promotes, you are reading a sponsor's interim update rather than an independent finding. That is the correct label for the AgelessRx announcement, stated without malice.

The Four-Question Audit for Any Longevity Claim

The framework compresses to four questions, runnable in under ten minutes on any claim, product page, or headline.

The verdict logic matters more than the questions. A 90-day, unblinded, sponsor-issued, biomarker-first readout answers a different question than a trial result does, namely feasibility, adherence, and early signals, and your beliefs should move only that far.

Two or more red flags means you are reading marketing that borrowed science's vocabulary. One red flag, especially duration, means promising but unproven. Zero red flags does not make a claim true; it earns the claim the right to be argued about.

Five Cases Through the Same Audit

To see the method transfer, run claims you have already met through the same grid.

The AgelessRx PEARL rapamycin trial is the instructive case because it partly passes. It was registered, its results were published, and the published readout reports gains in muscle mass and self-reported well-being in older adults at low doses. Now the audit sharpens instead of dismisses. AgelessRx affiliation warrants attention to design choices, small samples cap the strength of any conclusion, and well-being endpoints sit in the softest evidence tier while body-composition measures sit somewhere between surrogate and function. That is what a fair audit does. It grades evidence; it does not execute claims.

What This Means for Your Protocol

The practical verdict is short. Start nothing because of this readout. Stop nothing because of it. If you were weighing an AgelessRx product or protocol, the announcement changes the company's odds in a competition, not the evidence base for your body. A 90-day sponsor update is not the kind of signal that should move a stack you have tuned with months of your own sleep and recovery data.

Say precisely what would upgrade the verdict, so you recognize it when it arrives:

• 12 months of data, matching the contest window
• a control group and blinding, so placebo and expectancy become visible
• tested function as primary endpoints: grip, gait, cognition, immune response, not clocks or blood markers alone
• independent judging, which the contest's final scoring supplies
• peer-reviewed publication with methods you can actually read

Any one of those converts the story from feasibility to arguable. All of them arriving together is what winning looks like, and the earliest that can happen is quarters away.

Until then, keep the four questions next to your other habits. The longevity industry has a structural reason to keep issuing short-window readouts with long-window implications, because that asymmetry is the business model. Ten minutes and four questions will do more for your outcomes than most of the reasoning behind the purchases those headlines are engineered to trigger.